Laboratory:Hachioji
- TOP
- biochemical test
- enzymes and related materials
Laboratory:Hachioji
○enzymes and related materials
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
CK(CPK)
|
Serum
0.5 |
S09 ↓ A00 |
(10 days) |
2-4 | JSCC Standardization Compatibility Method | M62~287F45~163(U/L) | |
CK-MB(CPK-MB)
|
Serum
0.5 |
S09 ↓ A00 |
(6 days) |
2-4 |
Immunoblocking - UV method UV method (Ultraviolet absorption spectrophotometry) |
MB 25 or less TOTAL M 62~287 F 45~163 (U/L) |
|
CK-MB(CPK-MB)
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLIA CLIA (Chemiluminescent immunoassay) |
5.0 or less (ng/mL) | |
|
Serum 0.3 |
S09 ↓ A00 |
|
2-4 |
Agarose gel electrophoresis Electrophoresis method |
BB 2 or less MB 6 or less MM 93-99 (%) | |
|
Serum
0.5 |
S09 ↓ A00 |
(14 days) |
2-4 | JSCC Standardization Compatibility Method | 10~40(U/L) | |
|
Serum
0.5 |
S09 ↓ A00 |
(14 days) |
2-4 | JSCC Standardization Compatibility Method | 5~40(U/L) | |
|
Serum
0.5 |
S09 ↓ A00 |
(3 days) |
2-4 | IFCC Standardization Compliance Act | 124~222(U/L) | |
LD(LDH) Isozyme
|
Serum
0.3 |
S09 ↓ A00 |
|
2-4 |
Agarose gel electrophoresis Electrophoresis method |
LDH121~31LDH228~35LDH321~26LDH47~14LDH55~13(%) | |
Alkaline phospathase (ALP), IFCC
|
Serum
0.5 |
S09 ↓ A00 |
(1 month) |
2-4 | IFCC Standardization Compliance Act | 38~113(U/L) | |
Bone alkaline phosphatase (BAP)
|
Serum
0.8 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
Men 3.7-20.9 Premenopausal women 2.9-14.5 Postmenopausal women 3.8-22.6 (μg/L) | |
Placental alkaline phosphatase (PLAP)
|
Cerebrospinal fluid
0.5 |
A00 |
(28 days) |
2-6 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
(pg/mL) | |
Alkaline phosphatase isoenzymes(IFCC)
|
Serum
0.3 |
S09 ↓ A00 |
(21 days) |
2-4 |
Agarose gel electrophoresis Electrophoresis method |
ALP10.0~5.3 ALP236.6~69.2 ALP325.2~54.2 ALP50.0~18.1(%) |
|
γ-GT(γ-GTP)
|
Serum
0.5 |
S09 ↓ A00 |
(1 month) |
2-4 | JSCC Standardization Compatibility Method | M 70 or less F 30 or less (U/L) | |
Aldolase
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
UV Enzymatic method Enzymatic method |
2.1~6.1(U/L) | |
Cholinesterase (ChE)
|
Serum
0.5 |
S09 ↓ A00 |
(1 month) |
2-4 | JSCC Standardization Compatibility Method | M242~495F200~459(U/L) | |
Guanase
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
Enzymatic method Enzymatic method |
1.0 or less (U/L) | |
Adenosine deaminase (ADA)
|
Serum
0.6 |
S09 ↓ A00 |
|
2-4 |
Enzymatic method Enzymatic method |
5.0~20.0(U/L) | |
Leucine aminopeptidase (LAP)
|
Serum
0.5 |
S09 ↓ A00 |
(1 month) |
2-4 |
Enzymaticmethod(L-leucinep-nitroanilide) Enzymatic method |
35~73(U/L) | |
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 | JSCC Standardization Compatibility Method | 37~125(U/L) | |
Amylase (AMY)
|
Partial urine
0.5 |
U00 |
|
2-4 |
Enzymatic method(Gal-G2-CNP substrate) Enzymatic method |
65~700(U/L) | |
Amylase isoenzymes
|
Serum
0.3 |
S09 ↓ A00 |
|
2-4 |
Agarose gel electrophoresis Electrophoresis method |
TOTAL-S36.0~84.3TOTAL-P15.7~64.0(%) | |
Amylase isoenzymes
|
Partial urine
0.5 |
U00 |
|
2-4 |
Agarose gel electrophoresis Electrophoresis method |
TOTAL-S17.7~61.3TOTAL-P38.7~82.3(%) | |
Amylase, type P, quantitative
|
Serum
0.5 |
S09 ↓ A00 |
(21 days) |
2-4 | JSCC Standardization Compatibility Method | 21~64(U/L) | |
Lipase
|
Serum
0.5 |
S09 ↓ A00 |
(21 days) |
2-4 | Synthetic substrate colorimetric method | 13~55(U/L) | |
Trypsin
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
Latex agglutination turbidimetry LA (Latex agglutination immunoassay) |
210~570(ng/mL) | |
Pancreatic phospholipase A2 (pancreatic PLA2)
|
Serum 0.3 |
S09 ↓ A00 |
(21 days) |
2-5 |
RIA solid phase method IRMA (Immuno radio metric assay) |
130~400(ng/dL) | |
Pancreatic phospholipase A2 (pancreatic PLA2)
|
Plasma 0.3 |
PN2,PN5 ↓ A00 |
|
2-5 |
RIA solid phase method IRMA (Immuno radio metric assay) |
130~400(ng/dL) | |
Elastase 1
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 | Latex immunoturbidimetry | 300 or less (ng/dL) | |
Granulocyte elastase in cervical mucus
|
Cervical mucus
|
VP6 |
(1 month) |
2-4 | Latex agglutination immunoassay | 1.60 or less (μg/mL) | |
Tartrate resistant acid phosphatase (TRACP-5b)
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
Enzyme immunoassay(EIA) EIA (Enzyme immunoassay) |
Male 170-590 Female (YAM) 120-420 (mU/dL) | |
Lysozyme
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 | Nephelometry | 5.0~10.2(μg/mL) | |
Lysozyme
|
Partial urine
0.4 |
U00 |
|
2-4 | Nephelometry | Less than 0.1 (μg/mL) | |
Angiotensin I Converting enzyme (ACE)
|
Serum
0.7 |
S09 ↓ A00 |
|
2-4 | Kasahara method (Colorimetry) | 8.3~21.4(U/L) | |
N-acetyl glucosaminidase (NAG)
|
Partial urine
0.5 |
U00 |
|
2-4 |
Colorimetry Colorimetric method |
0.7~11.2(IU/L) | |
Pepsinogen
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 |
CLEIA CLEIA (Chemiluminescent enzyme immunoassay) |
See below | |
Matrix metalloproteinase 3 (MMP-3)
|
Serum
0.4 |
S09 ↓ A00 |
|
2-4 | LTIA | M36.9~121F17.3~59.7(ng/mL) | |
Gastric cancer risk screening (ABC classification)〔LA〕
|
Serum
1 |
S09 ↓ A00 |
(21 days) |
2-4 |
Latex agglutination turbidimetry CLEIA |
See below | |
Gastric cancer risk screening (ABC classification), eradicated〔LA〕
|
Serum
1 |
S09 ↓ A00 |
(21 days) |
2-4 |
Latex agglutination turbidimetry CLEIA |
See below | |
|
Serum
0.5 |
S09 ↓ A00 |
(21 days) |
2-4 | DCAP-P substrate method | 14.4 or less (U/L) | |
|
Serum
0.8 |
S09 ↓ A00 |
|
2-4 |
EIA CLEIA |
See below | |
|
Serum
0.5 |
S09 ↓ A00 |
|
2-4 | Protease method | 7 or less (U/L) | |
|
Serum
0.8 |
S09 ↓ A00 |
|
2-4 |
EIA CLEIA |